ALKBH5 and diabetes mellitus: Future studies should prioritize: clinical validation via prospective trials correlating ALKBH5 levels with DICM prognosis and treatment response; delivery optimization through developing cardiac‐targeted nanocarriers to enhance ALKBH5 specificity and reduce systemic exposure; and combination therapies by pairing ALKBH5 with iron chelators or SGs modulators to address multi‐pathway dysregulation in diabetes.